Non Hodgkin Lymphoma Clinical Trial
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
Summary
High-dose chemotherapy followed by blood stem cell transplantation is administered to lymphoma patients with an intention to cure. However, high-dose chemotherapy simultaneously causes damage to healthy tissues that frequently result in severe complications that lead to hospitalization and can be life threatening. These severe complications involve the blood, immune, gastro-intestinal systems, and other vital organs.
The purpose of this study is to determine if experimental therapy AB-205 (study drug) can prevent or reduce the occurrence and duration of the severe chemotherapy related complications when compared to placebo in patients with lymphoma undergoing treatment with high-dose chemotherapy and blood stem cell transplantation. All patients, whether treated with AB-205 or placebo, will receive standard preventive and supportive care therapies.
Eligibility Criteria
Inclusion Criteria:
Age ≥ 40 years old
Diagnosis of Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL)
Candidates for HDT-AHCT with one of the following conditioning regimens:
BEAM (carmustine, etoposide, cytarabine, melphalan)
BeEAM (bendamustine, etoposide, cytarabine, melphalan)
Achieved CR or PR prior to planned HDT
ECOG ≤ 2
Weight ≤ 1.6 × ideal body weight (IBW) per Devine formula
Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia
AST, ALT, and alkaline phosphatase < 3 × ULN
Creatinine clearance ≥ 30 ml/min (calculated by Cockcroft Gault)
LVEF ≥ 45% by MUGA or resting echocardiogram
Pulmonary function (FEV1 and corrected DLCO) ≥ 45% predicted
Willingness and ability to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions
Sexually active females of childbearing potential must have a negative urine pregnancy test and agree to use two accepted methods of contraception during the study and for 3 months after their last dose of study drug.
Male subjects who are sexually active and who are partners of females of childbearing potential: agreement to use two forms of contraception as in criterion 12 above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug
Ability to provide written informed consent.
Exclusion Criteria:
History of prior HCT
Primary CNS lymphoma
Lymphoma with CNS involvement at time of relapse prior to planned HDT-AHCT
Active malignancy other than the one for which the subject is undergoing HDT AHCT. Subjects with cervical carcinoma in situ or localized basal or squamous cell carcinoma treated with definitive surgery are eligible
Subjects with a serious concomitant medical condition that could interfere with the conduct of the clinical trial, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring IV antibiotics
Subjects with a known history of HIV
Subjects who have known hypersensitivity reactions to bovine (cow) proteins or documented allergy to DMSO
Subject has other conditions that in the opinion of the investigator would require reduced dose (intensity) of BEAM or BeEAM regimens
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 25 Locations for this study
Gilbert Arizona, 85234, United States More Info
Contact
Duarte California, 91010, United States More Info
Principal Investigator
Los Angeles California, 90095, United States More Info
Principal Investigator
Sacramento California, 95817, United States More Info
Principal Investigator
San Diego California, 92093, United States More Info
Principal Investigator
Denver Colorado, 80218, United States More Info
Principal Investigator
Miami Florida, 33136, United States More Info
Principal Investigator
Tampa Florida, 33612, United States More Info
Principal Investigator
Atlanta Georgia, 30322, United States More Info
Principal Investigator
Chicago Illinois, 60612, United States More Info
Principal Investigator
Indianapolis Indiana, 46202, United States More Info
Principal Investigator
Iowa City Iowa, 52242, United States More Info
Principal Investigator
Baltimore Maryland, 21201, United States More Info
Principal Investigator
Boston Massachusetts, 02114, United States More Info
Principal Investigator
Boston Massachusetts, 02215, United States More Info
Principal Investigator
Ann Arbor Michigan, 48109, United States More Info
Principal Investigator
Minneapolis Minnesota, 55455, United States More Info
Principal Investigator
Hackensack New Jersey, 07601, United States More Info
Principal Investigator
New York New York, 10065, United States More Info
Principal Investigator
New York New York, 10065, United States More Info
Principal Investigator
Columbus Ohio, 43210, United States More Info
Principal Investigator
Portland Oregon, 97239, United States More Info
Principal Investigator
Philadelphia Pennsylvania, 19111, United States More Info
Principal Investigator
Nashville Tennessee, 37203, United States More Info
Principal Investigator
Nashville Tennessee, 37203, United States More Info
Principal Investigator
Houston Texas, 77030, United States More Info
Principal Investigator
Seattle Washington, 98109, United States More Info
Principal Investigator
How clear is this clinincal trial information?